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Introduction
The complex pharmacodynamic mechanism of topiramate 
is currently approved for only two major diseases: epilepsy, 
mono or combined therapy, and preventing episodes of mi-
graine. However, there are many other studies that emphasize 
other potential clinical effects deriving from its complex action 
and leading to its use in acute nociceptive pain and neuropathic 
pain management.
Topiramate inhibits the action potential generated by repeat-
ed depolarization of neurons through blockage of sodium 
channels(Shank et al 1994; Perucca 1997) and some voltage-
dependent L-type calcium channels, inhibiting calcium current 
(Shank et al 1994; Shank et al 2000).
Studies have shown that lower concentrations of topiramate se-
lectively inhibits kainate receptor-mediated synaptic currents 
containing the GluR5 subunit (GLUK1) and also inhibits, reduc-
ing the effectiveness, the postsynaptic transmission of the ac-
tion potential by blocking the glutamate AMPA receptor (Braga 
et al 2009). Glutamate action on kainate receptors, facilitating 
transmission of excitatory potential, leads to the inhibition of 
GABA release, so topiramate inhibition of kainate receptors 
will favor GABA release and increase GABA(A) receptor-me-
diated inhibitory current (Braga et al 2009; Gryder et al 2003).
Topiramate inhibits carbonic anhydrase, CA-II and CA-IV 
isoenzymes, but this mecanism is unlikely to explain its anti-
convulsant and antinociceptive action (Wieczorkiewicz-Płaza 
et al 2004). Studies suggest that topiramate can be used to al-
leviate pain caused by diabetic neuropathy and migraines, in 
lower doses than those used to treat epilepsy (Spina et al 2004; 
Naegel et al 2010). 
Its normothymic stabilizing effect also occurs at lower doses 
than it does with anticonvulsant doses. Therefore, initially used 
as anticonvulsant, topiramate is currently used by psychiatrists 
to treat bipolar disorder, anxiety disorders, ADHD and substance 
abuse (Marcotte 1998; Maidment 2002).
The purpose of this study is to assess the action of topiramate 
on experimental models of nociceptive pain, with acute, suba-
cute and chronic administration.
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Analysis of results aims to assess not only the influence of 
topiramate on the latency of pain threshold stimulus emergence, 
but also pain threshold dynamics throughout the testing period. 
These measurements provide information on the immediate ac-
tion of topiramate (acute nociceptive pain) and on its action site: 
peripheral or central, depending on the test used and on the in-
tensity of the antinociceptive action compared to conventional 
analgesics. Pain threshold dynamics throughout the testing pe-
riod indicates how repeated administration of topiramate can 
influence the effectiveness of long-term therapy.
Material and methods
Experimental animals: 50 male Wistar white rats with initial 
weight between 110-240 g, obtained  from “Iuliu Haţieganu” 
University of Medicine and Pharmacy biobase, Cluj-Napoca. 
Experimental animals were kept in standard environmental and 
diet conditions, constant temperature and humidity, and natu-
ral light-dark cycle. The animals were randomly divided into 
five groups of 10 rats each one. The control group was inject-
ed intraperitoneally with 0.5 ml/100g saline solution (C). Two 
groups were injected with conventional analgesics, 50 mg/kg 
metamizole (M) and 10 mg/kg tramadol (T).
The investigated substance, topiramate, was administered in two 
different doses:  50 mg/kg (TPM50) and 10 mg/kg (TPM10).
Test methods
Paw pressure test was used in order to measure the analgesic 
effect using a Ugo Basile Analgesy-Meter (Italy). Paw pressure 
test is a mechanical analgesic method that measures the thresh-
old response to pain while gradually increasing pressure on the 
paw, estimating the weight when the rat withdraws its paw.
Hot plate test assesses heat sensitivity of the paw using a Ugo 
Basile hot plate (Italy) heated to 55°C. The plate was kept at a 
constant temperature of 55±0.1°C. Hot plate test is a thermo-
analgesic method that measures the threshold response to pain 
of the defense reaction of the paw to the heat stimulus. The an-
imals were each placed on the hot plate and the time of their 
first reaction to heat was recorded.
During tail-flick test, pain was induced by focusing an infrared 
light beam on the animal’s tail, about 4 cm from the tip of the 
tail. The reflex response is represented by the interval between 
light beam projection and tail flick, and is measured electroni-
cally. A Ugo Basile Tail-Flick Unit (Italy) was used.
For all three tests, the evaluation was made prior to injection 
(baseline), 1, 2, 4 hours after acute administration, and 2, 4, 6 
hours after subacute and chronic administration.
Statistical analysis was performed using Medcalc 12.5.0.0. The 
results were statistically processed and expressed as mean and 
standard deviation. ANOVA for repeated measures was used 
to test if the average values of the measurements were signifi-
cantly different between different testing times. Results were 
considered statistically significant for p<0.05. Pearson correla-
tion was subsequently applied to check if there is an association 
between measurement values determined through various tests 
and post-hoc tests consisting of pairwise comparisons between 
the groups of animals studied.
The experimental protocol is in accordance with the Council 
Directive 86/609/ECC of 24 November 1986 on animal studies 
and with the Romanian legislative framework.
Results
Threshold response to pain after single-dose administration 
of research substances in acute nociceptive pain 
The group injected with 0.9% NaCl (control group) did not 
show statistically significant differences between baseline val-
ues and those recorded after 1, 2, 4 and 24 hours, for any of the 
methods used to test pain response.
The group injected with metamizol (50 mg/kg) showed a sig-
nificant increase in threshold response to pain compared to 
baseline values, after one hour (p=0.03), 2 hours (p=0.05) and 
4 hours (p=0.05), changes recorded only if the measurements 
were performed using the hot plate.
The group injected with tramadol (10 mg/kg) showed a highly 
statistically significant increase in pain threshold compared to 
baseline values, one hour after administration (p<0.001), but 
only for measurements using the hot plate.
The group treated with TPM (50 mg/kg) showed a statistical-
ly significant increase in pain threshold for measurements us-
ing the hot plate. The increase was observed at all time points 
compared to the average values of baseline measurements, af-
ter one hour and 2 hours (p=0.001), 4 hours (p=0.012), and 24 
hours (p=0.03). Pain threshold analysis using tail flick test and 
the analgesy meter showed no statistically significant increase 
in pain threshold (Table 1).
Table 1. Pain threshold levels (mean±SD) 1, 2, 4 and 24 hours 
after administration of 50 mg/kg TPM
Table 2. Pain threshold levels (AM+/-SD) 1, 2, 4 and 24 hours 
after administration of 10 mg/kg TPM
TPM 50 mg/
kg
Paw pressure test Hot plate test Tail-flick test
Baseline 
(mean±SD)                 6.8±0.85 1.09±0.3 2.85±0.76
One hour 
(mean±SD)                 9.02±1.76
5.35±1.86
3.38±0.89
p=0.001
Two hours 
(mean±SD)                 8.2±1.84
5.48±1.91
3±1.39
p=0.001
Four hours 
(mean±SD)                 8±1.85
4.16±1.99
3.45±2.11
p=0.012
Twenty-
four hous 
(mean±SD)                
8.42±2.32
4.28±2.57
3.17±1.1
p=0.03
TPM 10 mg/kg
Paw pressure 
test
Hot plate test Tail-flick test
Baseline 
(mean±SD)                 6.85±0.77 1.09±0.12 2.9±0.55
One hour 
(mean±SD)                 11.6±4.32
4.7±1.54
4.6±1.88
p=0.001
Two hours 
(mean±SD)                 7.77±1.35
3.01±0.96
4.7±1.81
p=0.001
Four hours 
(mean±SD)                 8±1.06
3.04±1.57
3.25±1.4
p=0.02
Twenty-
four hours 
(mean±SD)                
10.2±2.25 4±1.88
4±0.94
p=0.008 p=0.009Rus et al 2013
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Measurements performed for the group treated with 10 mg/kg 
TPM showed significant increase in pain threshold compared 
to baseline measurements for paw pressure test after 24 hours 
(p=0.008), and for hot plate test at all time points: after one 
hour (p=0.001), 2 hours (p=0.001), 4 hours (p=0.02), and 24 
hours (p=0.009). Average tail-flick test measurements were not 
significantly different from baseline measurements (Table 2).
Analgesic effects of TPM, compared to the control group (C), 
metamizole (M) and tramadol (T) in acute administration 
Pain threshold following administration of 50 mg/kg TPM de-
termined a statistically significant increase compared to the con-
trol group and groups treated with metamizole and tramadol, at 
all time points in hot plate test (Table 3).
Thermoanalgesic test of the group treated with 10 mg/kg TPM 
revealed an increase in analgesic effect compared to the control 
group, at all time points (Table 3). Significant increase in pain 
sensitivity has been reported one hour and 24 hours in mechani-
cal test, and 2 hours in tail-flick test.  Compared to conventional 
analgesics, TPM 10 mg/kg has a more pronounced analgesic 
effect 1 hour and 24 hours in hot plate test. Compared to meta-
mizole, tenderness differences are also obvious one hour and 
24 hours in the tail-flick test.
The comparison between the groups treated with TPM at dif-
ferent doses only shows significant increase in pain threshold 
2 hours in the hot plate test (p<0.05) (Table 3).
Pain threshold evolution after administration of investigated 
substances for 14 days (subacute administration)
Analysis of the group treated with 0,9% NaCl showed no sta-
tistically significant differences from baseline in none of the 
applied tests. 
Analysis of the group treated with metamizole for 14 zile showed 
no statistically significant differences in baseline pain threshold 
when performing the mechanical and the thermal tests. Tail-
flick test showed statistically significant increase 2 hours after 
the administration of the daily dose.
There have been statistically significant increases in the group 
treated with tramadol 2 hours after performing the mechanical 
test. There have been no statistically significant differences for 
the hot plate test and the tail-flick test. 
For the group treated with 50 mg/kg TPM we obtained statisti-
cally significant increases in pain threshold 1 hour after in me-
chanical test. Hot plate test and tail-flick test showed no statis-
tically significant differences (Table 4).
Table nr. 4. Pain threshold levels (AM+/-SD) 2, 4, 6 hours af-
ter administration of 50 mg/kg TPM, test perfomed on day 14, 
compared to baseline levels.
Table 5. Pain threshold levels (AM+/-SD) 2, 4, 6 hours after 
administration of 10mg/kg TPM, test performed on day 14, 
compared to baseline levels
Analgesic effects of TPM compared to the control group 
(C), metamizole (M) and tramadol (T) groups, in subacute 
administration, depending on the procedure
The group undergoing subacute administration of TPM 50 re-
vealed significantly increased effects compared to the control 
group at all testing time during the hot plate test. Compared to 
tramadol, the pain threshold significantly increases from base-
line levels (p<0.05) during the same test. TPM 10 significant-
ly increases the pain threshold compared to the control group 
(baseline, 2 and 6 hours after) and to the groups treated with M 
and T groups (baseline) in hot plate test (Table 6). Mechanical 
Paw pressure test Hot plate test Tail-flick test
Lot Lot 1h 2h 4h 24h 1h 2h 4h 24h 1h 2h 4h 24h
TPM 50
mg/kg
C ns ns ns ns 0.001 p<0.05 p<0.05 p<0.05 ns ns ns ns
M ns ns ns ns 0.001 p<0.001 0.002 p<0.05 ns ns ns ns
T ns ns ns ns 0.002 p<0.001 p<0.001 p<0.05 ns ns ns ns
TPM10 ns ns ns ns ns p<0.05 ns ns ns ns ns
TPM 10 
mg/kg
C 0.007 ns ns 0.001 0.001 p<0.05 p<0.05 p<0.05 ns 0.03 ns ns
M ns ns ns ns 0.001 ns ns p<0.05 p<0.05 ns ns 0.01
T ns ns ns ns 0.005 ns ns p<0.05 ns ns ns ns
Table 3.  Statistical significance level when comparing the two tested doses of TPM with placebo, metamizole and tramadol 
in acute administration
TPM 50mg/
kg
Paw pressure 
test
Hot plate test Tail-flick test
Baseline 
(mean±SD)                 6.8±1.07 2.49±0.87 3.81±0.9
Two hour 
(mean±SD)                
9.45±1.84
2.18±0.54 3.76±1.19
p=0.01
Four hours 
(mean±SD)                 7.55±1.84 2.06±0.77 4.02±1.08
Six hours 
(mean±SD)                 8.95±1.51 2.16±0.95 3.59±0.67
TPM 10 mg/
kg
Paw pressure 
test
Hot plate test Tail-flick test
Baseline 
(mean±SD)                 9.22±2.91 3.46±1.24 4.26±1.23
Two hour 
(mean±SD)                 9.62±0.90 1.84±0.88 4.26±1.37
Four hours 
(mean±SD)                 10±2.16 1.61±0.55 4.30±1.71
Six hours 
(mean±SD)                 8.37±1.63 1.87±0.79 4.16±1.04Rus et al 2013
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test and tail-flick test do not show significant changes for TPM 
in any of the doses tested.
Table 6. Statistical significance when comparing the two doses 
of TPM with placebo, metamizol and tramadol, in subacute ad-
ministration, in hot plate test
Pain threshold levels after administration of research sub-
stances for 30 days (chronic administration)
The analysis of the control group mentioned no statistically 
significant differences between the mean pain threshold levels 
for any of the tests performed. Tail-flick test measurements for 
subjects treated with metamizole showed no statistically sig-
nificant differences. Mean paw pressure test determined statis-
tically significant increases in pain threshold between baseline 
and measurements performed after 2 hours (p=0.02) and 6 hours 
(p=0.002), metamizole acting as a painkiller in short-term acute 
pain, even after long-term administration. There have been no 
statistically significant differences in pain threshold in the group 
treated with tramadol, during the paw pressure test, hot plate 
test and tail-flick test.
Table 7. Pain threshold levels (AM+/-SD) 2, 4, 6 hours after 
administration of TPM10 and TPM50, compared to baseline 
levels, measurements performed on day 30, in the 3 used tests.
Analysis of the groups treated with TPM, compared with base-
line values, revealed no statistically significant increases in pain 
threshold, except from the group treated with 50 mg/kg TPM, 2 
hours in hot plate test. Baseline levels were relatively high and 
thus, pain threshold increases have not been statistically signifi-
cant even though there were high pain threshold levels  (Table 7).
Analgesic effects of TPM compared to placebo (P), metam-
izole (M) and tramadol (T), in chronic administration, de-
pending on the procedure
Chronic administration of TPM significantly increases baseline 
pain threshold levels so that there are no relevant increases in 
pain threshold after administration after the dose is stabilized. 
A balance dose is assumed to maintain a constant analgesic ef-
fect. Compared to the control group, pain threshold changes are 
obvious only in tail-flick test: baseline, 2, 4, and 6 hours after 
administration (Table 8).
TPM (50 mg/kg) does not show any significant increase in pain 
threshold when using the analgesy meter throughout the 30 
days of testing (Fig. 1). TPM (10 mg/kg) increases the thresh-
old response to pain mainly after 14 days, with significant pain 
threshold levels 2 hours (p=0.004) and 4 hours (p=0.01) after 
administration, as illustrated in Fig. 1. 
Pressure test performed on the group treated with TPM (50 mg/
kg) shows significant increases in baseline pain threshold levels 
on day 14 compared to the first testing day (p=0.004) and the 
last testing day (p=0.03). Baseline levels have increased after 
the first day of administration and remained high until the last 
testing day (p=0.008). Paw pressure test for TPM (50 mg/kg) 
shows elevated levels after the first administration, significantly 
higher than the values obtained at similar times 14 and 30 days 
after administration.
TPM (10 mg/kg) is similar to TPM (50mg/kg), recording sig-
nificant increase in pain threshold level after the first adminis-
tration, remaining elevated from the first day until the 14th day, 
then decreasing (Fig. 1).
Tail-flick test performed on the group treated with TPM (50mg/
kg) shows increased pain threshold levels after 30 days, statisti-
cally significant after 4 hours (p=0.006), compared to the val-
ues recorded at similar previous times (Fig. 1). TPM (10mg/kg) 
has similar behavior, but without significantly elevated levels 
throughout the 30 days of administration.
Figure 1. Pain threshold evolution for 30 days for the groups 
treated with TPM. The ordinate shows the response latency ac-
cording to procedure, the abscissa shows pain threshold evolu-
tion during the chosen testing times.
Hot plate test
Lot Lot Baseline 2h 4h 6h
TPM 50 
mg/kg
P p<0.05 p<0.05 p<0.05 p<0.05
M ns ns ns ns
T p<0.05 ns ns ns
TPM10 ns ns ns ns
TPM 10 
mg/kg
P p<0.05 p<0.05 ns p<0.05
M p<0.05 ns ns ns
T p<0.05 ns ns ns
TPM 50 mg/kg
Paw pressure 
test
Hot plate test Tail-flick test
Baseline 
(mean±SD)                 8.25±1.44 1.41±0.33 4.92±1.05
Two hour 
(mean±SD)                 7.58±1.22
2.67±1.07
4.13±1.11
p=0.02
Four hours 
(mean±SD)                 8.36±1.36 1.45±0.57 5.02±1.34
Six hours 
(mean±SD)                 7.56±1.32 1.64±0.21 4.94±1.42
 TPM 10 mg/kgPaw pressure 
test
Hot plate test Tail-flick test
Baseline 
(mean±SD)                 7.44±1.15 1.19±0.26 5.12±0.85
Two hour 
(mean±SD)                 8.45±0.84 1.81±0.84 5.09±1.21
Four hours 
(mean±SD)                 8.15±0.76 1.99±1.16 4.33±0.98
Six hours 
(mean±SD)                 7.93±1.06 1.41±0.26 4.83±0.87Rus et al 2013
Volume 5 | Issue 2 Page 74 
HVM Bioflux
http://www.hvm.bioflux.com.ro/
Discussions
Analysis of the groups treated with a single dose of TPM reveals 
obvious antinociceptive effects with statistically significant in-
crease in pain threshold at all time points when performing the 
hot plate test (p<0,05).
The results obtained in the first hours after administration are 
highly statistically significant (p=0.001) for both doses of TPM 
compared to baseline values.
The mechanical test and the tail-flick test showed no statisti-
cally significant changes in pain threshold which attests TPM’s 
central action.
Antinociceptive effect of both doses of TPM is rapid, with 
highly significant increase (p=0.001) one hour in the pressure 
test, compared to the control group and the groups treated with 
conventional analgesics. Maintenance of effect is obvious the 
mentioned test and remains significantly increased up to 24 
hours compared to the control group and the groups treated 
with tramadol and metamizole. The long half-life of TPM is 
highlighted by increased pain threshold 24 hours after the first 
administration (p=0.008), compared to baseline levels.
There have been few studies on TPM effect in somatic nocic-
eptive pain, one study indicating antinociceptive effects after 
intraperitoneal administration of 50 mg/kg and 100 mg/kg us-
ing hot plate test (Paudel et al 2011). However, results obtained 
for acute visceral pain indicate that at a dose of 10 mg/kg (same 
dose as the one we used) TPM has significant antinociceptive 
effect (Stepanovic-Petrovic et al 2008). The same study shows 
that the antinociceptive effect observed in TPM and GBP (gabap-
entin) occurs at doses which do not display significant adverse 
effects(Stepanovic-Petrovic et al 2008). Most preclinical stud-
ies indicate that TPM has antinociceptive effect in neuropathic 
pain(Wieczorkiewicz-Płaza et al 2004; Benoliel et al 2006), 
induced by various models of neuropathic pain but at doses of 
20-50 mg/kg. Efficiency at low doses observed in this study is 
consistent with other studies suggesting that low doses of TPM 
(10-20 mg/kg) are also effective in neuropathic pain (Benoliel 
et al 2006), side effects being dose dependent.
TPM has a complex mechanism of action involving inhibition of 
sodium and calcium channels, increasing the activity of chloride 
channels in neurons or glial cells, thus reducing the excitability 
of neuronal circuits (Shank et al 2008). These mechanisms are 
added by selective inhibition, in relatively low concentrations, of 
synaptic currents mediated by AMPA/kainate receptor-mediated 
glutamate (Gryder et al 2003;Braga et al 2009), and inhibition 
of carbonic anhydrase (CA-II, CA-IV isoenzymes)(Shank et al 
1994; Dodgson et al 2000). Some studies suggest modulation of 
potassium channels (Herrero et al 2002; Russo et al 2004) and 
action on certain proteins involved in neurotransmitter release 
from synaptic terminals (Okada et al 2005a). Despite these 
multiple pharmacodynamic properties of TPM, there is a com-
mon molecular mechanism suggesting that TPM can prevent 
ATP phosphorylation and its binding to certain receptors, ion 
channels or auxiliary proteins blocks their activation (Shank et 
al 2000; Angehagen et al 2004).
There are many other studies suggesting other potential clinical 
effects resulting from its complex action that can at least partly 
explain the action it has at low doses in acute nociceptive pain, 
as observed in our study.
It is important to remember that following nociceptive excita-
tion, glutamate acts mainly on AMPA receptors causing brief 
excitation only when the stimulus is increased or if there is re-
peated stimulus release, NMDA receptor activation or tachykinin 
NK1 and NK2-receptor activation in inflammatory processes 
(Petrenko et al 2003; Mc Roberts et al 2001).
TPM blocks AMPA/kainate receptors, reducing the excitabil-
ity induced by glutamate action (Braga et al 2009). TPM has a 
direct effect on neurotansmitter release, as shown in the stud-
ies conducted by Schiffer in 2001, showing that intraperitoneal 
administration of TPM at a dose of 25-50 mg/kg determines a 
50-70% decrease in nicotine-induced dopamine release in rats 
(Schiffer et al 2001; Shank et al 2008). Similar studies have 
shown that TPM acts on the release of monoamine in the pre-
frontal cortex in rats after release induction by means of vari-
ous procedures (Okada et al 2005a; Okada et al 2005b). These 
results suggest that TPM has a direct effect on the activity of 
certain proteins involved in exocytosis (Shank et al 2008) and, 
therefore, on the release of excitatory neurotransmitters.
The pharmacological effects of TPM seem to be related to the 
interaction with protein subunits in various ion channels or re-
ceptors, which in turn are activated by phosphorylation(Shank 
et al 2008). It was observed that the effect of TPM on the ac-
tivity of these proteins can be immediate, delayed or gradual 
(Angehagen et al 2004). The results obtained in several studies 
support the idea that TPM acts directly by binding to the site 
of protein phosphorylation activation, preventing gaining ATP 
access to this binding site and prolonging protein dephospho-
rylation, or indirectly by inhibiting certain protein kinases (c-
AMP protein kinase, protein kinase C, calmodulin) or activat-
ing certain phosphatases, such as calcineurin (Shank et al 2000; 
Angehagen et al 2004). If binding to this action site only occurs 
when these proteins are dephosphorylated, then this could be a 
possible explanation for the immediate or delayed action of TPM 
(Shank et al 2000; Angehagen et al 2004; Shank et al 2008).
TPM effect after repeated administration (14 days) using the 
paw pressure test is obvious through elevated baseline lev-
els compared to the control group and the groups treated with 
Lot
Tail-flick test
Baseline 2 h 4 h  6 h
C M T C M T C M T C M T
TPM 50 
mg/kg p<0.05 ns ns ns ns ns p<0.05 ns ns p<0.05 ns ns
TPM 10 
mg/kg p<0.05 ns ns p<0.05 ns ns p<0.05 ns ns p<0.05 ns ns
Table 8. Statistical significance of TPM in comparison with the control group (C) and conventional analgesics inthe tail-flick, 
30 days after administration.Rus et al 2013
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conventional analgesics. Increased threshold response to pain 
after TPM administration remains elevated (p<0.05) and obvi-
ous in comparison to the control group, at all time points. These 
clues are important for long-term therapy effectiveness and are 
reflected in clinical trials showing TPM efficacy in preventing 
therapy of migraine attack (Ruiz et al 2009; Naegel et al 2010), 
in neuropathic pain therapy (Wieczorkiewicz-Płaza et al 2004), 
and in the treatment of mental illnesses (Marcotte et al 1998; 
Maidment 2002).
The antinociceptive effect of TPM, 30 days after administra-
tion, shows that it increases the baseline pain threshold after the 
first dose, with maximum effect after 14 days, followed by a 
stable level, without significant increases compared to baseline 
levels. This process can be compared with dose titration until 
the medication has achieved the desired therapeutic effect, and 
reflects predictable linear kinetics, also encountered in clinical 
trials. Even if this study is based on a pharmacological approach 
and mainly investigates TPM action at certain doses and during 
a certain time interval, it also provides information regarding 
pharmacokinetics: long-term action, single-dose administration, 
long-term administration effectiveness.
Conclusions
TPM at a dose of 50 mg/kg has predominant central supraspi-
nal analgesic effect in acute nociceptive pain and for long-term 
administration. TPM at a dose of 10 mg/kg has predominant 
spinal analgesic effect (obvious by tail-flick test values) in 
acute nociceptive pain and for long-term administration. The 
analgesic effect of TPM is superior to the control group and to 
conventional analgesics tested in acute pain and throughout the 
entire testing period.
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